Now online!This study uncovers the molecular mechanism of LAG3 activation upon ligand engagement and its regulation by non-degradative polyubiquitination within the tumor microenvironment. The findings highlight LAG3/CBL coexpression as a promising biomarker for selecting suitable patients for LAG3-targeted immunotherapy.